Edition:
United Kingdom

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

291.86USD
2:58pm BST
Change (% chg)

$-2.22 (-0.76%)
Prev Close
$294.08
Open
$293.07
Day's High
$294.00
Day's Low
$291.18
Volume
109,013
Avg. Vol
1,458,956
52-wk High
$329.83
52-wk Low
$244.28

BIIB.O

Chart for BIIB.O

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.79
Market Cap(Mil.): $62,177.85
Shares Outstanding(Mil.): 211.43
Dividend: --
Yield (%): --

Financials

  BIIB.O Industry Sector
P/E (TTM): 19.31 30.82 32.14
EPS (TTM): 15.23 -- --
ROI: 17.59 14.45 13.99
ROE: 28.64 15.54 15.33

BRIEF-Paulson & Co takes share stake in Apple, dissolves share stake in Sarepta, Biogen

* Ups share stake in T-Mobile US Inc by 46.1 percent to 6.1 million shares - SEC filing

14 Aug 2017

BRIEF-Temasek Holdings takes stake in JPMorgan, Biogen, Celgene

* Temasek Holdings (Private) Ltd takes share stake in JPMorgan Chase & Co of 264,337 shares

14 Aug 2017

BRIEF-Biogen appoints Anabella Villalobos senior vice president, Biotherapeutic & Medicinal Sciences

* Biogen appoints Anabella Villalobos senior vice president, Biotherapeutic & Medicinal Sciences Source text for Eikon: Further company coverage:

31 Jul 2017

BRIEF-Abarca Health signs reimbursement contract with Biogen for select products

* Signed value-based reimbursement contract with Biogen for select products in Biogen's leading multiple sclerosis portfolio​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

27 Jul 2017

BRIEF-Biogen says in July 2017 learned that prosecution office of Milan is investigating interactions with some healthcare providers in Italy - SEC Filing

* Biogen says in July 2017 learned that prosecution office of Milan is investigating interactions with some healthcare providers in Italy - SEC Filing

25 Jul 2017

After strong quarter, Biogen rolls out growth strategy

Biogen Inc laid out long-term plans to strengthen its mainstay multiple sclerosis (MS) business, develop more neuroscience drugs and shop for late-stage assets, after reporting robust second-quarter results on Tuesday.

25 Jul 2017

UPDATE 3-After strong quarter, Biogen rolls out growth strategy

* Spinraza sales of $203 mln smash analyst estimates of $70 mln

25 Jul 2017

BRIEF-Biogen CEO: "we will explore deals of all sizes"

* Biogen CEO: "overall, we maintain our global market share in multiple sclerosis (treatments)"

25 Jul 2017

US STOCKS-Caterpillar, McDonald's to lift S&P, Dow at open

* Futures up: Dow 96 pts, S&P 6.5 pts, Nasdaq 5 pts (Adds details, comment, updates prices)

25 Jul 2017

BRIEF-Biogen reports Q2 EPS $4.07

* Biogen reports record quarterly revenues of $3.1 billion, raises full year revenue guidance

25 Jul 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $133.66 -0.51
Pfizer Inc. (PFE.N) $33.35 -0.01
Novartis AG (NOVN.S) CHF80.95 -1.00
Merck & Co., Inc. (MRK.N) $62.57 -0.13
Roche Holding Ltd. (ROG.S) CHF244.80 -0.30
Roche Holding Ltd. (RO.S) CHF247.40 0.00
Bayer AG (BAYGn.DE) €108.25 +0.15
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €83.03 +0.45
GlaxoSmithKline plc (GSK.L) 1,507.50 +3.50

Earnings vs. Estimates